指南与共识消化系统肿瘤

术后循环肿瘤DNA联合共识分子亚型可更好地预测III期结肠癌结局:一项前瞻性队列研究

Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
指南 / 共识 · Eur J Cancer · 2022-05-27

这项前瞻性观察性队列研究纳入165例III期结肠癌患者,检测化疗前后血浆循环肿瘤DNA(ctDNA)并结合共识分子亚型(CMS)分类。化疗前或化疗后可检测到ctDNA均与更差的无复发性生存(RFS)显著相关,且为独立预后因素;将ctDNA、CMS和临床风险联合可重新定义风险分层,更好地预测复发。

要点

  • 化疗前可检测到ctDNA者RFS显著更差(HR 3.585,P<0.001)。
  • 化疗后可检测到ctDNA者RFS显著更差(HR 3.337,P=0.005)。
  • 联合ctDNA、CMS和临床风险可重新定义III期结肠癌风险分层。

核心结论

  • 术后ctDNA提示残留病灶,联合CMS分类和反映肿瘤内在特征的临床风险,可重新定义III期结肠癌的风险分层并更好地预测复发。

研究设计与样本

  • 前瞻性、观察性队列研究,纳入165例III期结肠癌患者。
  • 采用197个癌症相关基因的靶向测序面板检测肿瘤组织及化疗前后血浆中的体细胞变异。
  • 采用788个基因的靶向RNA测序面板进行CMS分类。
  • 分析了151份化疗前血浆和124份化疗后血浆,130例患者完成CMS分类。

主要发现

  • 化疗前样本中ctDNA可检测率为15.9%,化疗后样本中为8.9%。
  • 化疗前样本可检测到ctDNA者RFS显著更差(HR 3.585,P<0.001),化疗后样本可检测到ctDNA者RFS显著更差(HR 3.337,P=0.005)。
  • 多因素分析中,化疗前ctDNA状态(HR 5.538,P<0.001)和化疗后ctDNA状态(HR 3.272,P=0.037)仍与RFS独立相关。
  • 按重新定义的复发风险分层,中危患者(ctDNA阴性且CMS4/T4或N2肿瘤)复发可能性是低危患者(ctDNA阴性且CMS1-3/T3N1肿瘤)的5.3倍(HR 5.269,P=0.025)。
  • 高危患者(ctDNA阳性)复发可能性是低危患者的14.6倍(HR 14.590,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precise methods for risk stratification to guide adjuvant chemotherapy for stage III colon cancers are needed. Here, we combined circulating tumor DNA (ctDNA) with consensus molecular subtype (CMS) to improve risk stratification in stage III colon cancers. METHODS: We conducted a prospective, observational cohort study of 165 patients with stage III colon cancers. Somatic variants in tumor tissues and plasmas collected pre- and post-chemo were detected via a targeted sequencing panel of 197 cancer-related genes. CMSs classification was characterized using a targeted RNA sequencing panel of 788 genes. RESULTS: We analyzed 151 pre-chemo and 124 post-chemo plasmas, while 130 patients were CMSs classified. ctDNA was detectable in 15.9% pre-chemo and 8.9% post-chemo samples. Significantly worse recurrence-free survival (RFS) was seen if ctDNA was detectable in pre-chemo samples (hazard ratio [HR], 3.585; P < 0.001) or in post-chemo samples (HR, 3.337; P = 0.005). Pre-chemo ctDNA (HR, 5.538; P < 0.001) and post-chemo ctDNA status (HR, 3.272; P = 0.037) remained independently associated with RFS in multivariate analysis. According to the redefined recurrence risk stratification, mid-risk patients (ctDNA-negative with CMS4/T4 or N2 tumors) were 5.3 times (HR, 5.269; P = 0.025) more likely to relapse than low-risk patients (ctDNA-negative with CMS1-3/T3N1 tumors), while high-risk patients (ctDNA-positive) were 14.6 times (HR, 14.590; P < 0.001) more likely to relapse. CONCLUSIONS: Postoperative ctDNA indicating residual disease, combined with CMSs classification and clinical risk reflecting the intrinsic characteristics of tumors, can redefine risk stratification of stage III colon cancers and better predict relapse.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Li Y, Mo S, Zhang L, et al. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. Eur J Cancer. 2022. PMID: 35636041. doi:10.1016/j.ejca.2022.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。